Cargando…
Development of new malaria diagnostics: matching performance and need
Despite advances in diagnostic technology, significant gaps remain in access to malaria diagnosis. Accurate diagnosis and misdiagnosis leads to unnecessary waste of resources, poor disease management, and contributes to a cycle of poverty in low-resourced communities. Despite much effort and investm...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4981959/ https://www.ncbi.nlm.nih.gov/pubmed/27515426 http://dx.doi.org/10.1186/s12936-016-1454-8 |
_version_ | 1782447683668017152 |
---|---|
author | Bell, David Fleurent, Alessandra E. Hegg, Michael C. Boomgard, John D. McConnico, Caitlin C. |
author_facet | Bell, David Fleurent, Alessandra E. Hegg, Michael C. Boomgard, John D. McConnico, Caitlin C. |
author_sort | Bell, David |
collection | PubMed |
description | Despite advances in diagnostic technology, significant gaps remain in access to malaria diagnosis. Accurate diagnosis and misdiagnosis leads to unnecessary waste of resources, poor disease management, and contributes to a cycle of poverty in low-resourced communities. Despite much effort and investment, few new technologies have reached the field in the last 30 years aside from lateral flow assays. This suggests that much diagnostic development effort has been misdirected, and/or that there are fundamental blocks to introduction of new technologies. Malaria diagnosis is a difficult market; resources are broadly donor-dependent, health systems in endemic countries are frequently weak, and the epidemiology of malaria and priorities of malaria programmes and donors are evolving. Success in diagnostic development will require a good understanding of programme gaps, and the sustainability of markets to address them. Targeting assay development to such clearly defined market requirements will improve the outcomes of product development funding. Six market segments are identified: (1) case management in low-resourced countries, (2) parasite screening for low density infections in elimination programmes, (3) surveillance for evidence of continued transmission, (4) clinical research and therapeutic efficacy monitoring, (5) cross-checking for microscopy quality control, and (6) returned traveller markets distinguished primarily by resource availability. While each of these markets is potentially compelling from a public health standpoint, size and scale are highly variable and continue to evolve. Consequently, return on investment in research and development may be limited, highlighting the need for potentially significant donor involvement or the introduction of novel business models to overcome prohibitive economics. Given the rather specific applications, a well-defined set of stakeholders will need to be on board for the successful introduction and scaling of any new technology to these markets. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12936-016-1454-8) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4981959 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-49819592016-08-13 Development of new malaria diagnostics: matching performance and need Bell, David Fleurent, Alessandra E. Hegg, Michael C. Boomgard, John D. McConnico, Caitlin C. Malar J Commentary Despite advances in diagnostic technology, significant gaps remain in access to malaria diagnosis. Accurate diagnosis and misdiagnosis leads to unnecessary waste of resources, poor disease management, and contributes to a cycle of poverty in low-resourced communities. Despite much effort and investment, few new technologies have reached the field in the last 30 years aside from lateral flow assays. This suggests that much diagnostic development effort has been misdirected, and/or that there are fundamental blocks to introduction of new technologies. Malaria diagnosis is a difficult market; resources are broadly donor-dependent, health systems in endemic countries are frequently weak, and the epidemiology of malaria and priorities of malaria programmes and donors are evolving. Success in diagnostic development will require a good understanding of programme gaps, and the sustainability of markets to address them. Targeting assay development to such clearly defined market requirements will improve the outcomes of product development funding. Six market segments are identified: (1) case management in low-resourced countries, (2) parasite screening for low density infections in elimination programmes, (3) surveillance for evidence of continued transmission, (4) clinical research and therapeutic efficacy monitoring, (5) cross-checking for microscopy quality control, and (6) returned traveller markets distinguished primarily by resource availability. While each of these markets is potentially compelling from a public health standpoint, size and scale are highly variable and continue to evolve. Consequently, return on investment in research and development may be limited, highlighting the need for potentially significant donor involvement or the introduction of novel business models to overcome prohibitive economics. Given the rather specific applications, a well-defined set of stakeholders will need to be on board for the successful introduction and scaling of any new technology to these markets. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12936-016-1454-8) contains supplementary material, which is available to authorized users. BioMed Central 2016-08-11 /pmc/articles/PMC4981959/ /pubmed/27515426 http://dx.doi.org/10.1186/s12936-016-1454-8 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Commentary Bell, David Fleurent, Alessandra E. Hegg, Michael C. Boomgard, John D. McConnico, Caitlin C. Development of new malaria diagnostics: matching performance and need |
title | Development of new malaria diagnostics: matching performance and need |
title_full | Development of new malaria diagnostics: matching performance and need |
title_fullStr | Development of new malaria diagnostics: matching performance and need |
title_full_unstemmed | Development of new malaria diagnostics: matching performance and need |
title_short | Development of new malaria diagnostics: matching performance and need |
title_sort | development of new malaria diagnostics: matching performance and need |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4981959/ https://www.ncbi.nlm.nih.gov/pubmed/27515426 http://dx.doi.org/10.1186/s12936-016-1454-8 |
work_keys_str_mv | AT belldavid developmentofnewmalariadiagnosticsmatchingperformanceandneed AT fleurentalessandrae developmentofnewmalariadiagnosticsmatchingperformanceandneed AT heggmichaelc developmentofnewmalariadiagnosticsmatchingperformanceandneed AT boomgardjohnd developmentofnewmalariadiagnosticsmatchingperformanceandneed AT mcconnicocaitlinc developmentofnewmalariadiagnosticsmatchingperformanceandneed |